Cancer cells can be synchronized to the G2/M phase by delivering an anti-microtubule agent (e.g., paclitaxel or another taxane) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. This synchronization can be taken advantage of by treating the cancer cells with radiation therapy after the combined action of the delivering step and the applying step has increased a proportion of cancer cells that are in the G2/M phase. The optimal frequency and field strength will depend on the particular type of cancer cell being treated. For certain cancers, this frequency will be between 125 and 250 kHz (e.g., 200 kHz) and the field strength will be at least 1 V/cm.

Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. In one embodiment, the method comprising the steps of: (i) applying controlled thermal energy at 40-43° C. for a first predetermined time period to damage and weaken tumor cells of a tumor in a patient; (ii) administering pulsed high intensity focused ultrasound (pHIFU) in a first ultrasound mode to the tumor cells in the patient so as to damage the tumor cells without increasing the thermal energy; and (iii) administering low intensity focused ultrasound (LIFU) in a second ultrasound mode to further damage the tumor cells at a temperature of 39-43° C. for a second predetermined time period while performing observation of the tumor cells by ultrasonic thermometry.

A cell destruction method includes providing an anionic biomarker that comprises a magnetic material such as an iron or an iron compound. The anionic biomarker is introduced into an organism having pathogen cells with a negative charge. The anionic biomarkers are attracted to the negative charges of the pathogen and couple thereto. The anionic biomarker may also have a coupler portion that further aids in the anionic biomarker coupling to and being bound to the pathogen cell and/or cell wall. An electric field may be produced to cause the anionic biomarkers and/or the negative charges of the pathogen cell to polarize on or along the pathogen cell. A magnetic field is directed to cause the anionic biomarker, or magnetic material thereof to move and damage the cell. The magnetic field may be an alternating magnetic field that causes the magnetic material to oscillate and damage the cell wall.

It discloses a proteolysis targeting chimeric molecule, a preparation method and an application thereof. The proteolysis targeting chimeric molecule provided by the disclosure can inhibit the expression of BCR-ABL and/or CRBN protein in BCR-ABL and/or CRBN positive leukemia K562 cells to varying degrees, and thus can be used to prepare drugs for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule with n=3 has excellent photo-isomerization activity, and can be used in preparation of the reagents or drugs for light-regulated degradation of BCR-ABL and/or CRBN protein. The disclosure also provides a method for synthesizing the series of proteolysis targeting chimeric molecules.

The present invention relates to antigen binding sites, compositions and uses thereof in the treatment of conditions associated with pathogenic proteins. In one example the condition is Alzheimer's disease.

Methods for producing and utilizing primed platelets are provided, in which platelets are primed for release of specific granule types and/or active compounds by irradiation, for example with electromagnetic radiation, an electrical field, and/or a magnetic field. Such irradiation can be performed ex vivo or in vivo. Such primed platelets have utility in treating inflammatory conditions, neurodegenerative conditions, and/or joint and tendon related injuries.

Systems and methods for temporarily altering a tissue characteristic at a target region, such as the blood-brain barrier, include causing an ultrasound transducer to transmit acoustic energy to the target region at a transmission frequency; acquiring a cumulative harmonic response from at least the target region; and operating the transducer based at least in part on the acquired cumulative harmonic response.

Methods for the generation of electrochemical plasma activated aqueous chemotherapeutics (EPAAC) solutions are described. These solutions have been found to selectively reduce the proliferation of human pancreatic cancer cells, with no toxic effects for healthy cells.

Methods for the generation of electrochemical plasma activated aqueous chemotherapeutics (EPAAC) solutions are described. These solutions have been found to selectively reduce the proliferation of human pancreatic cancer cells, with no toxic effects for healthy cells.

Provided is a method of reducing a number of viable microbes, including contacting microbes with an antibiotic compound and applying pulses of electricity having a duration of between about 50 nanoseconds and about 900 nanoseconds. The pulses of electricity may have an intensity between about 20 kV/cm and about 40 kV/cm. The pulses of electricity may be applied at a frequency of between about 0.1 Hz and about 10 Hz. The microbes may be a gram-negative or a gram-positive strain of bacteria and the antibiotic may be applied at a concentration for a duration, wherein applying the antibiotic to the strain at the concentration for the duration does not reduce a viable number of bacteria of the strain as much, or at all, when the pulses of electricity are not also applied.